{
    "clinical_study": {
        "@rank": "77520", 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether T900607-sodium is effective and safe in\n      treating ovarian cancer."
        }, 
        "brief_title": "Study of T900607-Sodium in Previously Treated Patients With Ovarian Cancer.", 
        "condition": "Ovarian Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Ovarian Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n          -  Histologically or cytologically confirmed diagnosis of ovarian cancer\n\n          -  Subjects must have received 1-2 regimens of prior chemotherapy (with one containing\n             paclitaxel)\n\n          -  At least 18 years of age\n\n          -  Bidimensionally measurable disease amenable to CT scanning. At least one lesion must\n             be least 1 X 1 cm in size.\n\n          -  Karnofsky performance status of at least 70%\n\n          -  Estimated life expectancy of at least 12 weeks\n\n          -  Females of childbearing potential must have a negative pregnancy test and agree to\n             use an effective contraceptive\n\n          -  Subject must be able to comply with study procedures and follow-up examinations.\n\n          -  Signed written informed consent\n\n          -  Lab Values (obtained \u2264 7 days prior to study enrollment):\n\n          -  ANC at least 1.5x10e9/L,\n\n          -  Platelet count at least 100x10e9/L,\n\n          -  Hemoglobin at least 8.5 g/dL,\n\n          -  Creatinine within 2 times upper limit of normal\n\n          -  AST and ALT within 3 times upper limit of normal\n\n          -  Bilirubin within 1.5 times upper limit of normal\n\n          -  Albumin great than 2.5 g/dL\n\n          -  INR < 1.5 for subjects without anticoagulants\n\n        Exclusion Criteria\n\n          -  Severe, concurrent disease, infection or co-morbidity that, in the judgment of the\n             investigator, would make the subject inappropriate for enrollment\n\n          -  NYHA Class III/IV cardiac disease, left ventricular ejection fraction (LVEF) of <50%,\n             or acute anginal symptoms\n\n          -  Patients who have received any investigational agent within 4 weeks of enrollment\n\n          -  Patients who are pregnant or breast-feeding\n\n          -  History of prior malignancy other than ovarian cancer within the last 5 years, except\n             for adequately treated basal cell or squamous cell skin cancer or carcinoma in situ\n             of the cervix\n\n          -  History of central nervous system metastases or carcinomatous meningitis\n\n          -  Major surgery within 4 weeks of enrollment"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "35", 
        "firstreceived_date": "August 8, 2002", 
        "id_info": {
            "nct_id": "NCT00043446", 
            "org_study_id": "T-607-005"
        }, 
        "intervention": {
            "intervention_name": "intravenous T900607-sodium", 
            "intervention_type": "Drug"
        }, 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "La Jolla", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92037"
                    }, 
                    "name": "Scripps Health Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90033"
                    }, 
                    "name": "USC Women's and Children's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94115"
                    }, 
                    "name": "University of California San Francisco"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "Massachusetts General Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Buffalo", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14263"
                    }, 
                    "name": "Roswell Park Cancer Center"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "overall_official": {
            "affiliation": "Tularik", 
            "last_name": "Kerrie Boyd", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00043446"
        }, 
        "source": "Tularik", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tularik", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2002", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2004"
    }, 
    "geocoordinates": {
        "Massachusetts General Hospital": "42.358 -71.06", 
        "Roswell Park Cancer Center": "42.886 -78.878", 
        "Scripps Health Center": "32.839 -117.277", 
        "USC Women's and Children's Hospital": "34.052 -118.244", 
        "University of California San Francisco": "37.775 -122.419"
    }
}